PROTECT YOUR PATH TO APPROVAL WITH MEDIDATA EDGE TRIAL ASSURANCE

Machine learning improves data quality and scales to meet increasing demand

When analyzing data quality issues in **24** RECENT STUDIES

across **18** THERAPEUTIC AREAS

Edge Trial Assurance found **1479** AVOIDABLE DATA QUALITY ISSUES

spanning **30M+** DATA POINTS

and **22K** PATIENTS

learning **90K+** RULES

Former FDA Statistical Reviewers **at Medidata** indicated that

22%

Of data quality issues found across 24 studies had potential to delay regulatory approval

Data Quality Issues Across 24 Studies

Anomaly Categories Detected



A Top 25 Global Pharma

Data Quality Issues most likely to delay regulatory approval in **10** Studies in **6** Therapeutic Areas



A Top Global Pharma with HQ in APAC

Data Quality Issues most likely to delay regulatory approval in **1** Study in **1** Therapeutic Area

A Top 10 Global Med-Device

Data Quality Issues most likely to delay regulatory approval in **2** Studies in **2** Therapeutic Areas



The difference between an FDA approval and an FDA letter: **Medidata Edge Trial Assurance**



medidata